Now, four more celebrities who are at high risk for developing severe Covid-19 symptoms are getting in on Pfizer’s Covid-related ad campaigns in the new year. For musician and filmmaker Questlove, being overweight puts him at high risk, and for actress Jean Smart, it’s diabetes. “In fact, you can be one of almost 200 million Americans with a high risk factor that makes Covid even riskier,” P!nk says. The latest campaign aired just a couple weeks after Pfizer and BioNTech unveiled a commercial promoting updated booster shots featuring Stewart. That’s Covid-19,” Stewart says as she sharpens a long sword in the kitchen.
Pfizer’s S1P receptor modulator for treating ulcerative colitis, etrasimod, which was at the center of a billion-dollar buyout from Arena Pharma, has now taken another step forward. On Wednesday, the pharma announced that the FDA had accepted for review the NDA for etrasimod in patients with “moderately-to-severely active” ulcerative colitis. Pfizer stated that the FDA’s decision will be expected in the second half of next year. At week 52, 32.1% of patients receiving the drug hit remission, compared to 6.7% on placebo, showing a 25.4% differential and a p-value of p=˂.001. Last year, Bristol Myers Squibb had its S1P Zeposia approved by the FDA to treat ulcerative colitis, which earned BMS around $134 million in 2021.1 month ago Endpoints News
Oncolytic viruses — viruses that can selectively replicate in cancer cells and kill them — have been steadily attracting investment and curiosity. ” I got involved through a mutual friend who called and said, ‘these guys are trying to spin a company out,'” Edwards said. Per Edwards, initial efforts in other companies were looking at multiple cytokines as payloads to these oncolytic viruses, or only have one cytokine that is extra potent. At least in the US, only one oncolytic virus has made it past the FDA: Amgen’s Imlygic for certain types of melanoma. There are a few companies that have been looking at oncolytic viruses as well.3 months ago Endpoints News
GSK can breathe a little easier after a Florida federal judge dismissed thousands of claims that Zantac and related heartburn products caused cancer, triggering a boost in premarket trading on Wednesday. On Tuesday, Judge Robin Rosenberg tossed the remaining claims in liver, bladder, pancreatic, esophageal, and stomach cancers, upon determining that the allegations were based on “flawed” and “unreliable” evidence. GSK’s stock $GSK was down 2% on Wednesday at $37.16, after reportedly jumping about 14% in early trading. Plaintiffs argued that ranitidine can transform into NDMA in the body or on the shelf in high temperatures, and in 2020, regulators requested the recall of all ranitidine products. More than 2,450 plaintiffs filed suits in the MDL, or had cases transferred to the Florida federal court.1 month ago Endpoints News
Now, Chen is back with a new biotech with the same end goal — to get into unresponsive tumors. Instead, Normunity wants to break down the wall that’s standing between the immune system and cancer cells using antibodies. Once that happens, either the body’s normal immune system (hence the name) or a different immunotherapy can enter the tumors and do their job. “We can then use the antibodies to specifically unlock this phenomenon to allow the immune system to work or enable the other users to work,” Chen explained. Chen and Humphrey both emphasized the ongoing collaboration between Normunity and Chen’s lab at Yale, noting that they were next door to each other.3 months ago Endpoints News
While Biogen’s Q3 revenue dipped by 10% versus the prior year, the company focused its earnings call on two bright prospects — recently unveiled positive results for lecanemab, its anti-amyloid Alzheimer’s follow-up to Aduhelm, and its potential ALS drug tofersen. Even with a full approval, however, questions still remain on whether CMS will cover the drug. An FDA decision on tofersen, an antisense drug designed to treat a genetic subset of ALS, is coming next April. The FDA, however, has never approved a drug based on a drug candidate’s purported neurofilament-lowering effect. Biogen’s global MS revenue, including Ocrevus royalties, declined 11% for the quarter, and Tecfidera’s revenue decreased 32% due to the entrance of generics.3 months ago Endpoints News
California biotech Gritstone bio was given an $80 million credit facility in the summer, following the trend of several biotechs extending cash through loans. Now the biotech is making another financial move as it lifts the cover on some vaccine trials. While it is working on candidates in the HIV and tumor space, Gritstone is focused on two candidates to counter SARS-CoV-2. The move comes as it gently pulls the curtain back on early Phase I results for its ongoing trials investigation of its “self-amplifying” mRNA (samRNA) vaccine candidates against SARS-CoV-2. Earlier this year it received an $80 million credit facility from Hercules Capital and Silicon Valley Bank, initially drawing $20 million with another $10 million available to withdraw by March 15 of next year.3 months ago Endpoints News
The University of Tennessee, Knoxville, welcomes fans to campus Saturday, Oct. 29, for the football game against the University of Kentucky. Fans are encouraged to visit utsports.com/gameday/football for the latest updates on game information. For more information, including downtown parking options for fans without a football parking permit, visit the Parking and Transit Services football web page. Fans are invited to stay for the watch party and cheer on the Vols throughout the game. Unmanned aircraft systems are prohibited on university property beginning four hours before the scheduled kickoff time of a football game, during the game and for two hours after the conclusion of the game.3 months ago News